Correlation Between Virax Biolabs and Neurobo Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and Neurobo Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and Neurobo Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virax Biolabs Group and Neurobo Pharmaceuticals, you can compare the effects of market volatilities on Virax Biolabs and Neurobo Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of Neurobo Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and Neurobo Pharmaceuticals.

Diversification Opportunities for Virax Biolabs and Neurobo Pharmaceuticals

0.3
  Correlation Coefficient

Weak diversification

The 3 months correlation between Virax and Neurobo is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and Neurobo Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurobo Pharmaceuticals and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with Neurobo Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurobo Pharmaceuticals has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and Neurobo Pharmaceuticals go up and down completely randomly.

Pair Corralation between Virax Biolabs and Neurobo Pharmaceuticals

Given the investment horizon of 90 days Virax Biolabs Group is expected to under-perform the Neurobo Pharmaceuticals. In addition to that, Virax Biolabs is 1.4 times more volatile than Neurobo Pharmaceuticals. It trades about -0.17 of its total potential returns per unit of risk. Neurobo Pharmaceuticals is currently generating about 0.14 per unit of volatility. If you would invest  406.00  in Neurobo Pharmaceuticals on April 22, 2024 and sell it today you would earn a total of  45.00  from holding Neurobo Pharmaceuticals or generate 11.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Virax Biolabs Group  vs.  Neurobo Pharmaceuticals

 Performance 
       Timeline  
Virax Biolabs Group 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Virax Biolabs Group are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Virax Biolabs showed solid returns over the last few months and may actually be approaching a breakup point.
Neurobo Pharmaceuticals 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Neurobo Pharmaceuticals are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental drivers, Neurobo Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Virax Biolabs and Neurobo Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Virax Biolabs and Neurobo Pharmaceuticals

The main advantage of trading using opposite Virax Biolabs and Neurobo Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, Neurobo Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will offset losses from the drop in Neurobo Pharmaceuticals' long position.
The idea behind Virax Biolabs Group and Neurobo Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Complementary Tools

Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins